| Primary |
| Atrial Fibrillation |
27.4% |
| Product Used For Unknown Indication |
18.9% |
| Atrial Flutter |
9.1% |
| Drug Use For Unknown Indication |
6.6% |
| Hypertension |
5.4% |
| Arrhythmia |
5.0% |
| Ventricular Tachycardia |
3.6% |
| Tachyarrhythmia |
3.0% |
| Gout |
2.8% |
| Myocardial Infarction |
2.6% |
| Cardiac Disorder |
2.2% |
| Heart Rate Irregular |
2.0% |
| Anticoagulant Therapy |
1.6% |
| Supplementation Therapy |
1.6% |
| Supraventricular Tachycardia |
1.6% |
| Prophylaxis |
1.4% |
| Ventricular Arrhythmia |
1.4% |
| Arrhythmia Prophylaxis |
1.2% |
| Essential Hypertension |
1.2% |
| Insomnia |
1.2% |
|
| Infusion Site Phlebitis |
13.4% |
| Pulmonary Toxicity |
10.6% |
| Phlebitis |
10.1% |
| Hyperthyroidism |
6.7% |
| Toxicity To Various Agents |
6.7% |
| Tremor |
6.1% |
| Drug Interaction |
5.6% |
| Neurotoxicity |
5.6% |
| Neuromyopathy |
5.0% |
| Off Label Use |
3.9% |
| Pneumonia |
3.9% |
| Ventricular Tachycardia |
3.4% |
| Interstitial Lung Disease |
2.8% |
| Pulmonary Oedema |
2.8% |
| Electrocardiogram Qt Prolonged |
2.2% |
| Injection Site Phlebitis |
2.2% |
| Keratopathy |
2.2% |
| Lung Disorder |
2.2% |
| Respiratory Failure |
2.2% |
| Ventricular Fibrillation |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
23.0% |
| Atrial Fibrillation |
17.4% |
| Product Used For Unknown Indication |
13.0% |
| Hypertension |
5.7% |
| Ventricular Tachycardia |
5.7% |
| Arrhythmia |
4.4% |
| Ventricular Fibrillation |
4.3% |
| Cardiac Failure |
3.4% |
| Atrial Flutter |
3.2% |
| Angina Pectoris |
2.9% |
| Hypothermia |
2.9% |
| Septic Shock |
1.9% |
| Spinal Osteoarthritis |
1.6% |
| Acute Myocardial Infarction |
1.6% |
| Essential Hypertension |
1.6% |
| Cardio-respiratory Arrest |
1.5% |
| Coronary Artery Disease |
1.5% |
| Heart Rate Irregular |
1.5% |
| Ventricular Tachyarrhythmia |
1.5% |
| Diabetes Mellitus |
1.4% |
|
| Ventricular Extrasystoles |
8.2% |
| Syncope |
7.1% |
| Ventricular Tachycardia |
6.6% |
| Electrocardiogram Qt Prolonged |
5.6% |
| Liver Disorder |
5.6% |
| Respiratory Failure |
5.6% |
| Rhabdomyolysis |
5.6% |
| Torsade De Pointes |
5.6% |
| Infusion Site Phlebitis |
5.1% |
| Phlebitis |
5.1% |
| Sedation |
5.1% |
| Ventricular Fibrillation |
5.1% |
| Renal Failure Acute |
4.6% |
| Drug Interaction |
4.1% |
| Hypothyroidism |
4.1% |
| Parkinsonism |
4.1% |
| Thrombocytopenia |
3.6% |
| Cardiac Arrest |
3.1% |
| Multi-organ Failure |
3.1% |
| Myositis |
3.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
26.0% |
| Product Used For Unknown Indication |
22.6% |
| Hypertension |
8.5% |
| Atrial Fibrillation |
6.4% |
| Cardiac Failure Chronic |
5.6% |
| Cardiac Failure |
5.2% |
| Cardiac Disorder |
3.4% |
| Diabetes Mellitus |
3.0% |
| Prophylaxis |
2.8% |
| Arrhythmia |
2.6% |
| Type 2 Diabetes Mellitus |
2.4% |
| Rheumatoid Arthritis |
2.1% |
| Hyperlipidaemia |
1.3% |
| Myocardial Infarction |
1.2% |
| Angina Pectoris |
1.2% |
| B-cell Lymphoma |
1.2% |
| Univentricular Heart |
1.2% |
| Coronary Artery Disease |
1.1% |
| Osteoporosis |
1.1% |
| Blood Cholesterol Increased |
1.0% |
|
| Renal Failure Acute |
9.8% |
| Vomiting |
9.3% |
| Ventricular Tachycardia |
8.2% |
| Rhabdomyolysis |
5.7% |
| Ventricular Fibrillation |
5.7% |
| Death |
5.2% |
| Stevens-johnson Syndrome |
5.2% |
| Thrombocytopenia |
5.2% |
| Atrial Fibrillation |
4.6% |
| Syncope |
4.6% |
| Urinary Tract Infection |
4.6% |
| Hypoglycaemia |
4.1% |
| White Blood Cell Count Decreased |
4.1% |
| Arrhythmia |
3.6% |
| Lung Disorder |
3.6% |
| Platelet Count Decreased |
3.6% |
| Weight Decreased |
3.6% |
| Bradycardia |
3.1% |
| Cerebrovascular Accident |
3.1% |
| Renal Impairment |
3.1% |
|
| Interacting |
| Atrial Flutter |
11.7% |
| Renal Failure Chronic |
9.5% |
| Pneumonia |
8.8% |
| Ventricular Tachycardia |
8.8% |
| Atrial Fibrillation |
8.0% |
| Ill-defined Disorder |
8.0% |
| Drug Use For Unknown Indication |
7.3% |
| Antiplatelet Therapy |
4.4% |
| Product Used For Unknown Indication |
4.4% |
| Pulmonary Embolism |
4.4% |
| Pain |
3.6% |
| Essential Hypertension |
2.9% |
| Hyperlipidaemia |
2.9% |
| Sleep Disorder |
2.9% |
| Anticoagulant Therapy |
2.2% |
| Cardiac Disorder |
2.2% |
| Hypertension |
2.2% |
| Pain In Extremity |
2.2% |
| Supraventricular Tachycardia |
2.2% |
| Acute Myocardial Infarction |
1.5% |
|
| Drug Interaction |
20.5% |
| Cardioactive Drug Level Increased |
10.3% |
| Blood Creatinine Increased |
7.7% |
| Myopathy |
7.7% |
| Retroperitoneal Haematoma |
7.7% |
| Alanine Aminotransferase Increased |
5.1% |
| Hypersensitivity |
5.1% |
| Torsade De Pointes |
5.1% |
| Electrolyte Imbalance |
2.6% |
| Hepatic Steatosis |
2.6% |
| Hepatitis Cholestatic |
2.6% |
| Hypoaesthesia |
2.6% |
| Melaena |
2.6% |
| Periorbital Oedema |
2.6% |
| Rash |
2.6% |
| Renal Cell Carcinoma |
2.6% |
| Somnolence |
2.6% |
| Therapeutic Response Unexpected With Drug Substitution |
2.6% |
| Unresponsive To Stimuli |
2.6% |
| Urinary Incontinence |
2.6% |
|
